Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration

Your place for beaking medical news and career advice from top medical recruiters

TARRYTOWN, N.Y. and PARIS, July 28, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)  and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. As part of the agreement, the two companies will jointly develop a programmed cell death protein 1 (PD-1) inhibitor currently in Phase 1 testing and plan to initiate clinical trials in 2016 with new therapeutic candidates based on ongoing, innovative preclinical programs. read more

Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer

INGELHEIM, Germany & SEOUL, South Korea–(EON: Enhanced Online News)–Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd today announced an exclusive license and collaboration agreement for the development and global commercialisation rights, except South Korea, China and Hong Kong, of HM61713, a novel 3rd generation EGFR targeted therapy for the treatment of EGFR mutation-positive lung cancer. Under the terms of the agreement Hanmi will receive an initial payment of USD 50 million and is entitled to potential milestone payments of USD 680 million, plus tiered double-digit royalties on future net sales. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, similar requirements outside the U.S., and other customary closing conditions. read more

Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA

DUBLIN and WESTLAKE VILLAGE, Calif., July 27, 2015 /PRNewswire/ — Allergan plc (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Allergan’s pending acquisition of KYTHERA.  read more

Sprint Bioscience Enters into Collaboration with Bayer Healthcare on Tumor Metabolism Program

Sprint Bioscience AB (publ) (Sprint Bioscience) and Bayer HealthCare (Bayer) have entered into a collaboration and license agreement for the research, development, and commercialization of oncological drug candidates. Under the agreement, Sprint Bioscience licenses an early-stage inhibitor program targeting tumor metabolism to Bayer. Subsequently, Bayer will have full control over further development and worldwide commercialization rights for potential cancer therapeutics and diagnostics. read more

Gerresheimer Will Acquire Centor – Higher Profitability Expected

Gerresheimer AG, one of the leading partners to the pharma and healthcare industry worldwide, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding Inc. “Centor is the highly profitable market leader for plastic vials and closures in the prescription retail market. This is a perfect fit to extend our product offering from packaging of parenterals to the packaging of oral drugs in the US. We expect that this acquisition will increase shareholder value significantly,” said Uwe Röhrhoff, Chief Executive Officer of Gerresheimer AG.

Florida Hospital Association endorses VisiQuate Big Data Analytics Solutions

SANTA ROSA, Calif.–(BUSINESS WIRE)–Today, VisiQuate announced the Florida Hospital Association’s (FHA) endorsement of its analytics solutions. FHA is the second statewide body to recommend a specific analytics partner. In June of 2014, the Healthcare and Hospital Association of Pennsylvania gave VisiQuate a similar endorsement. read more


Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.